Vontobel Financial Products GmbH Share Price

Certificat

DE000VM103A2

Delayed Deutsche Boerse AG 19:03:11 19/06/2024 BST
99.81 EUR +0.07% Intraday chart for Vontobel Financial Products GmbH
Current month+0.51%
1 month+0.46%
Date Price Change
19/06/24 99.81 +0.07%
18/06/24 99.74 +0.19%
17/06/24 99.55 -0.23%
14/06/24 99.78 -0.11%
13/06/24 99.89 -0.01%

Delayed Quote Deutsche Boerse AG

Last update June 19, 2024 at 07:03 pm

More quotes

Static data

Product typeReverse Convertibles
Buy / SellCALL
Underlying ROCHE HOLDING AG
IssuerLogo Issuer Vontobel Vontobel
WKN VM103A
ISINDE000VM103A2
Date issued 18/09/2023
Strike 258 CHF
Maturity 20/09/2024 (93 Days)
Parity 0.26 : 1
Emission price 100
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 100
Lowest since issue 89.43

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
247.9 CHF
Average target price
278.1 CHF
Spread / Average Target
+12.16%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW